Effect of advanced glycation end-products on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells

Kidney International

Volumn 66, Issue 3, 2004, Pages 1099-1106

  Rashid, Gloria ^b   Benchetrit, Sydney ^b   Fishman, Dina ^b   Bernheim, Jacques ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b NONE

Author keywords

AGEs; Endothelial cells; eNOS; TNF

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BETA 2 MICROGLOBULIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; RECEPTOR ANTIBODY; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENZYME SYNTHESIS; GENE EXPRESSION; GLYCATION; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; UMBILICAL VEIN;

EID: 4344600477     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00860.x     Document Type: Article

References (43)

1. VLASSARA H, BUCALA R, STRIKER L: Biology of disease: Pathogenic effects of advanced glycosylation. Biochemical, biologic, and clinical implications for diabetes and aging. J Lab Invest 70:138-151, 1994
2. RAJ DSC, CHOUDHURY D, WELBOUME TC, LEVI M: Advanced glycation end products: A nephrologist's perspective. Am J Kidney Dis 35:365-380, 2000
3. BAYNES J: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
4. SCHMIDT AM, HORI O, BRETT J, et al: Cellular receptors for advanced glycation end products: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Artheroscler Thromb 14:1521-1528, 1994
5. BROWNLEE M, CERAMI A, VLASSARA H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
6. BUCALA R, CERAMI A: Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv Pharmcol 23:1-34, 1992
7. VLASSARA H, FUH H, DONNELLY T, CYBULSKY M: Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1:447-456, 1995
8. MAKITA Z, RADOFF S, RAAYfIELD EJ, et al: Advanced glycation end products in diabetic nephropathy. N Engl J Med 325:836-842, 1991
9. BRETT J, SCHMIDT AM, ZOU YS, et al: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699-1712, 1993
10. MORIGI M, ANGIOLETTI S, IMBERTI B, et al: Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-Kb-dependent fashion. J Clin Invest 101:1905-1915, 1998
11. SENGOELGE G, FODINGER M, SKOUPY S, et al: Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. Kidney Int 54:1637-1651, 1998
12. MIYATA T, ODA O, INAGI R, et al: Beta 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243-1252, 1993
13. MANTOVANI A, BUSSOLINO F, DEJANA E: Cytokine regulation of endothelial cell function. FASEB J 6:2591-2599, 1992
14. TRACEY KJ, CERAMI A: Tumor necrosis factor: An update review of its biology. Crit Care Med 21:S415-S422, 1993
15. CARLOS TM, HARLAN JM: Leukocyte-endothelial adhesion molecules. Blood 7:2068-2101, 1994
16. IKEDA K, HIGASHI T, SANO H, et al: N (carboxymethyl) lysine protein adducts is a major immunological epitope in proteins modified with advanced glycation end products of the maillard reaction. Biochem 35:8075-8083, 1996
17. KISLINGER T, FU C, HUBER B, et al: N-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signalling pathways and modulate gene expression. J Biol Chem 274:31740-31749, 1999
18. HABEEB AF: Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 14:328-336, 1966
19. JAFFE EA, NACHMAN RL, BECKER CG, MINICK CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphological and immunologic criteria. J Clin Invest 52:2745-2756, 1973
20. WAUTIER JL, GUILLAUSSEAU PJ: Advanced glycation end products, their receptors and diabetic angiopathy. Diab Metab 27:535-542, 2001
21. MIYATA T, INAGI R, IIDA Y, et al: Involvement of β2-microglobulin modified with advanced glycated end products in the pathogenesis of hemodialysis-associated amyloidosis: Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor and interleukin-1. J Clin Invest 93:521-528, 1994
22. IIDA Y, MIYATA T, INAGI R, et al: β2-Microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: Role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Commun 201:1235-1241, 1994
23. NEUHAUS T, GUDRUN T, GRUENWALD E, et al: Tumor necrosis factor-α gene expression and production in human umbilical arterial endothelial cells. Clin Sci 98:461-470, 2000
24. RANTA V, ORPANA A, CARPEN O, et al: Human vascular endothelial cells produce tumor necrosis factor-α in response to proinflammatory cytokine stimulation. Crit Care Med 27:2184-2187, 1999
25. BECKMAN JA, CREAGER MA, LIBBY P: Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA 287:2570-2581, 2002
26. STENVINKEL P: Inflammatory and atherosclerotic interactions in the depleted uremic patients. Blood Purif 19:53-61, 2001
27. VLASSARA H, BROWNLEE M, MANOGUE KR, et al: Cachecin/TNF and IL-1 induced by glucose-modified proteins: Role in tissue remodeling. Science 240:1546-1548, 1988
28. RASHID G, LUZON A, KORZETS Z, et al: The effect of advanced glycation end products and aminoguanidine on TNF-α production by rat peritoneal macrophages. Perit Dial Inter 21:122-129, 2001
29. AMORE A, CIRINA P, MITOLA S, et al: Nonenzymathically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells. Kidney Int 51:27-35, 1997
30. HASEGAWA G, NAKANO K, SAWADA M, et al: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40:1007-1012, 1991
31. YOSHIZUMI M, PERRELLA MA, BURNETT JC, LEE M: Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 73:205-209, 1993
32. LU JL, SCHMIEGE LM, KUO L, LIAO JC: Downregulation of endothelial constitutive nitric oxide synthase expression by lipopolysaccharide. Biochem Biophys Res Commun 225:1-5, 1996
33. PARK L, RAMAN KG, LEE KJ, et al: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-1031, 1998
34. WAUTIER JL, ZOUKOURIAN C, CHAPPEY O, et al: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97:238-243, 1996
35. DUBEY R, JACKSON E, LUSCHER TF: Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cells. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest 96:141-149, 1995
36. GARG UC, HASSID A: Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774-1777, 1989
37. CHAKRAVARTHY U, HAYES RG, STITT AW, et al: Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 47:945-952, 1998
38. ROJAS A, ROMAY S, GONZALEZ D, et al: Regulation of endothelial nitric oxide expression by albumin-derived advanced glycosylation end products. Circ Res 86:e50-e54, 2000
39. UHLMANN S, REZZOUG K, FRIEDRICHS U, et al: Advanced glycation end products quench nitric oxide in vitro. Graefe's Arch Clin Exp Opthalmol 240:860-866, 2002
40. KHAN BV, HARRISON DG, OLBRYCH MT, et al: Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 93:9114-9119, 1996
41. KUBES P, SUZUKI M, GRANGER DN: Nitric oxide. An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88:4651-4655, 1991
42. OEMAR BS, TSHUDI MR, GODOY N, et al: Reduced endothelial endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 97:2494-2498, 1998
43. ISHIDA A, SASAGURI T, KOSAKA C, et al: Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generation vasodilator in vascular smooth muscle cells. J Biol Chem 272:10050-10057, 1997